FierceBiotech 2026년 3월 19일 Lilly's obesity discovery partner Fauna sees weight loss potential in hibernating mammals
FierceBiotech 2026년 3월 19일 Lilly's triple-G bet lowers blood sugar, prompts 16.8% weight loss in phase 3 diabetes trial
Endpoints News 2026년 3월 19일 Updated: Lilly’s triple-G comparable with Mounjaro, first Phase 3 diabetes data suggest
BioPharma Dive 2026년 3월 12일 Lilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compounders
Endpoints News 2026년 3월 12일 Lilly warns of impurity risk in certain compounded forms of Mounjaro and Zepbound
Endpoints News 2026년 3월 11일 Lilly plots GLP-1 pill production boost in China, $500M pledge to South Korea
Pharmaron 2026년 3월 11일 Lilly beefs up oral GLP-1 capacity with $3B manufacturing pledge in China - Fierce Pharma
Endpoints News 2026년 3월 6일 Lilly plucks Flagship, bluebird vet for regenerative medicine unit; Novo's new China president
Endpoints News 2026년 2월 24일 Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market
BioPharma Dive 2026년 2월 23일 Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study
Endpoints News 2026년 2월 23일 Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial